Skip to main content

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Trial Status: Complete

Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and cohort 3 (Other SCC) are currently open

Inclusion Criteria

  • histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1: Note: Cohort closed to further enrolment) or Squamous Cell Carcinoma head and neck cancer (cohort 2) or Squamous Cell Carcinoma other than HNSCC (cohort 3) for which there is no curative therapy available.
  • tumor that carries a missense HRAS mutation ith a variant allele frequency (VAF) > 20%.
  • Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status
  • Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.
  • At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
  • ECOG PS 0 or 1
  • Acceptable liver function
  • Acceptable renal function
  • Acceptable hematologic status • Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥ 35%) may be enrolled despite a serum albumin < 3.5 g/dL.

Exclusion Criteria

  • Prior treatment with an FTase inhibitor
  • History of relevant coronary heart disease or myocardial infarction within last 3 years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or serious cardiac arrhythmia requiring medication except atrial fibrillation.
  • Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day
  • - Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C


Mayo Clinic in Arizona
Status: ACTIVE


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE


Emory University Hospital / Winship Cancer Institute
Emory University Hospital Midtown
Status: ACTIVE


Dana-Farber Cancer Institute


Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE


Mayo Clinic in Rochester

New York

New York
Memorial Sloan Kettering Cancer Center
Contact: Alan Loh Ho
Phone: 646-888-4235


Oklahoma City
University of Oklahoma Health Sciences Center


Fox Chase Cancer Center
University of Pennsylvania / Abramson Cancer Center


M D Anderson Cancer Center
Status: ACTIVE

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in

subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors

that carry HRAS mutations and for whom there is no curative therapy available. Subjects with

information available on tumor HRAS status previously generated are eligible. All subjects

must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a

retrospective testing of HRAS gene status at a central facility.

Subjects will be enrolled into three nonrandomized cohorts:

- Cohort 1: Malignant thyroid tumors with HRAS mutations (cohort is closed).

- Cohort 2: Squamous Cell Carcinoma Head and Neck Cancer with HRAS mutations.

- Cohort 3: Squamous Cell Carcinoma (SCC) with HRAS mutations other than HNSCC

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Kura Oncology, Inc.

  • Primary ID KO-TIP-001
  • Secondary IDs NCI-2015-01835, NCI-2015-00949
  • ID NCT02383927